7 research outputs found
Correlating Changes in Spot Filling Factors with Stellar Rotation: The Case of LkCa 4
We present a multi-epoch spectroscopic study of LkCa 4, a heavily spotted
non-accreting T Tauri star. Using SpeX at NASA's Infrared Telescope Facility
(IRTF), 12 spectra were collected over five consecutive nights, spanning
1.5 stellar rotations. Using the IRTF SpeX Spectral Library, we
constructed empirical composite models of spotted stars by combining a warmer
(photosphere) standard star spectrum with a cooler (spot) standard weighted by
the spot filling factor, . The best-fit models spanned two
photospheric component temperatures, = 4100 K (K7V) and 4400 K
(K5V), and one spot component temperature, = 3060 K (M5V) with an
of 0.3. We find values of to vary between 0.77 and 0.94 with
an average uncertainty of 0.04. The variability of is periodic
and correlates with its 3.374 day rotational period. Using a mean value for
to represent the total spot coverage, we calculated spot
corrected values for and . Placing these values alongside
evolutionary models developed for heavily spotted young stars, we infer mass
and age ranges of 0.45-0.6 and 0.50-1.25 Myr, respectively. These
inferred values represent a twofold increase in the mass and a twofold decrease
in the age as compared to standard evolutionary models. Such a result
highlights the need for constraining the contributions of cool and warm regions
of young stellar atmospheres when estimating and to infer
masses and ages as well as the necessity for models to account for the effects
of these regions on the early evolution of low-mass stars.Comment: 21 pages, 9 Figures; Accepted for publication in Ap
Bone cancer pain: The effects of the bisphosphonate alendronate on pain, skeletal remodeling, tumor growth and tumor necrosis
Patients with metastatic breast, lung or prostate cancer frequently have significant bone cancer pain. In the present report we address, in a single in vivo mouse model, the effects the bisphosphonate alendronate has on bone cancer pain, bone remodeling and tumor growth and necrosis. Following injection and confinement of green fluorescent protein-transfected murine osteolytic tumor cells into the marrow space of the femur of male C3H/HeJ mice, alendronate was administered chronically from the time the tumor was established until the bone cancer pain became severe. Alendronate therapy reduced ongoing and movement-evoked bone cancer pain, bone destruction and the destruction of sensory nerve fibers that innervate the bone. Whereas, alendronate treatment did not change viable tumor burden, both tumor growth and tumor necrosis increased. These data emphasize that it is essential to utilize a model where pain, skeletal remodeling and tumor growth can be simultaneously assessed, as each of these can significantly impact patient quality of life and survival.Peer reviewe